A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

NCT00851890 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis C Virus Infection

Interventions

DRUG: ABT-333
OTHER: Placebo for ABT-333
DRUG: Pegylated interferon
DRUG: Ribavirin

Sponsor

AbbVie (prior sponsor, Abbott)